It seems like a "we're not in Kansas anymore" moment. The validity of Merck & Co., Inc.’s patents for its 16-year old blockbuster diabetes treatment Januvia (sitagliptin) were upheld by a US district court 29 September, bolstering market exclusivity for the drug until May 2027.
The decision is subject to appeal. Nevertheless, Merck’s victory over patent challenger Viatris Inc. was hailed as a big...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?